SATIVEX

This brand name is authorized in Estonia, Spain, Finland, Ireland, Israel, New Zealand, Poland, United Kingdom

Active ingredients

The drug SATIVEX contains a combination of these active pharmaceutical ingredients (APIs):

1 Dronabinol UNII 7J8897W37S - DRONABINOL

Dronabinol is an active ingredient of cannabis, which has complex effects on the CNS, including central sympathomimetic activity. Dronabinol exerts its action by activating CB1 and CB2 recepors which makes it a CNS active medicine. Read about Dronabinol

2 Cannabidiol UNII 19GBJ60SN5 - CANNABIDIOL

Cannabidiol is indicated for the treatment of seizures associated with Lennox‑Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older. Read about Cannabidiol

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N02BG10		N Nervous system → N02 Analgesics → N02B Other analgesics and antipyretics → N02BG Other analgesics and antipyretics
Discover more medicines within N02BG10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1645275
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 72544
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 173653
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 174194
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7230
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 13391
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100290348